Fosfomycin: An oral agent for urinary infection caused by extended spectrum beta-lactamase producing organisms

References 

1. Falagas ME, Kotsantis IK, Vouloumanou EK, Rafailidis PI. Antibiotics versus placebo in the treatment of women with uncomplicated cystitis: A meta-analysis of randomized controlled trials. J Infect. 2009;(i):91–102
2. Woodford N, Ward ME, Kaufmann ME, Turton J, Fagan EJ, James D, et al. Community and Hospital Spread of Escherichia coli producing CTX-M extended β-lactamases in the UK. J Antimicrob Chemother. 2004;54(4):735–743
   • MEDLINE
   • CrossRef
3. Schito GC, Naber KG, Botto H, Palou J, Mazzei T, Gualco L, et al. The ARSEC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents. 2009 Jun 6;
4. Garau J. Other microbials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline. Clin Microbiol Infect. 2008 Jan;14(Suppl. 1):198–202
   • CrossRef
5. Galatti L, Sessa A, Mazzaglia G, Pecchioli S, Rossi A, Cricelli C, et al. Antibiotic prescribing for acute and recurrent cystitis in primary care: a 4 year descriptive study. J Antimicrob Chemother. 2006;57:551–556
   • MEDLINE
   • CrossRef
6. FDA licensing information on fosfomycin . Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails[accessed 02.07.09]
7. British Society for Antimicrobial Chemotherapy Standardised Disc Susceptibility Testing Method . Version 8. available at: http://www.bsac.org.uk/susceptibility_testing/bsac_standardized_disc_susceptibility_method.cfmJanuary 2009;[accessed 02.07.09]